Weekly Breast Cancer Research Update – April 2016 – #3

April 18th, 2016

Exercise hope for treatment of tumours

NBCF-funded researchers at Edith Cowan University in WA have shown that instead of traditional advice to avoid exercise, those with advanced stage breast cancer can actually reduce tumour size through regular exercise. Although incurable, Dr Nicholas Hart says researchers are trying to slow the progress of bone metastasis and their evidence shows that exercise provides a ‘survival benefit’.

 

Dressed to kill: Tailoring a suit for tumour-penetrating cancer meds

For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumours. Now researchers have developed a new method using tiny nanoparticles that is four times more effective at penetrating solid tumour than other strategies currently in use at inhibiting the growth of aggressive breast cancer.

 

Researchers slow breast cancer growth by blocking cell’s ability to process fat

Researchers at the Spanish Institute for Research in Biomedicine in Barcelona have discovered that breast cancer cells need to take up fat from their environment in order to grow. The finding provides a novel way to slow or possibly block tumour growth, raising hopes of new and potentially less toxic cancer treatments.

 

Genetic link confirmed between non-invasive breast cancer (DCIS) and development of invasive disease

Scientists have confirmed inherited genetic links between non-invasive cancerous changes found in the milk ducts – known as ductal carcinoma in situ (DCIS) – and the development of invasive breast cancer, meaning that a family history of DCIS could be as important to assessing a woman’s risk as a history of invasive breast cancer.

NBCF note: Although breast cancer screening has reduced deaths it also identifies increasing numbers of DCIS, which may not always develop into invasive cancer but are currently treated with surgery and/ or radiotherapy. Professor Sandra O’Toole is developing a test to better predict which DCIS patients will actually benefit from these treatments, and which can be safely spared.